Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-05-09 00:00:00 ET · period of report 2022-05-05 · accession 0001209191-22-027848 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-05-09 | 2022-05-05 | PCVX | Fairman Jeff | VP, Research | S - Sale | $25.80 | -888 | 325.3K | -0.3% | -$22.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-05 | S | D | 888 | $25.80 | 325,339 | I By Fairman Family Trust | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $25.58 to $26.19. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |